Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 90.77M P/E - EPS this Y -157.30% Ern Qtrly Grth -
Income -6.72M Forward P/E -5.12 EPS next Y 3.60% 50D Avg Chg -3.00%
Sales 18.69M PEG -0.10 EPS past 5Y - 200D Avg Chg -14.00%
Dividend N/A Price/Book 2.41 EPS next 5Y 100.00% 52W High Chg -39.00%
Recommedations 1.70 Quick Ratio 4.24 Shares Outstanding 9.49M 52W Low Chg 19.00%
Insider Own 25.73% ROA -16.64% Shares Float 5.02M Beta 0.93
Inst Own 33.53% ROE -31.60% Shares Shorted/Prior 171.63K/153.29K Price 9.58
Gross Margin 19.15% Profit Margin -35.94% Avg. Volume 13,416 Target Price 28.50
Oper. Margin -76.90% Earnings Date May 28 Volume 6,048 Change -0.62%
About MediWound Ltd.

MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. The company also develops EscharEx, which has completed Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds; and MW005, which is in phase I/II for the treatment of low-risk basal cell carcinoma. MediWound Ltd. was incorporated in 2000 and is headquartered in Yavne, Israel.

MediWound Ltd. News
04/25/24 MediWound to Present New Data from EscharEx® Phase II Studies at Three Leading Wound Care Conferences
04/17/24 Strength Seen in MediWound (MDWD): Can Its 14.3% Jump Turn into More Strength?
03/25/24 Wall Street Analysts See a 76.89% Upside in MediWound (MDWD): Can the Stock Really Move This High?
03/25/24 What Makes MediWound (MDWD) a Good Fit for 'Trend Investing'
03/24/24 MediWound Ltd. (NASDAQ:MDWD) Just Reported Full-Year Earnings: Have Analysts Changed Their Mind On The Stock?
03/21/24 MediWound (MDWD) Reports Q4 Loss, Tops Revenue Estimates
03/21/24 MediWound Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Company Update
03/14/24 MediWound to Report Fourth Quarter and Full Year 2023 Financial Results
03/07/24 Retail investors who hold 38% of MediWound Ltd. (NASDAQ:MDWD) gained 15%, institutions profited as well
03/06/24 MediWound (MDWD) Moves 7.1% Higher: Will This Strength Last?
02/12/24 MediWound Announces Positive Results in Head-to-Head Comparison of EscharEx® vs. SANTYL® within the ChronEx Phase II Randomized Controlled Study
02/05/24 MediWound to Participate in Two Upcoming Investor Conferences
02/01/24 Here's Why We're Not Too Worried About MediWound's (NASDAQ:MDWD) Cash Burn Situation
01/15/24 MediWound (MDWD)'s Technical Outlook is Bright After Key Golden Cross
01/09/24 Wall Street Analysts Think MediWound (MDWD) Could Surge 134.77%: Read This Before Placing a Bet
01/09/24 MediWound (MDWD): Strong Industry, Solid Earnings Estimate Revisions
01/09/24 MediWound Announces that FDA has Accepted for Review the Supplement to the NexoBrid BLA to Include Pediatric Patients with Severe Thermal Burns
12/28/23 MediWound Secures Additional U.S. Department of Defense Funding to Advance NexoBrid® Development for the U.S. Army
12/21/23 MediWound Announces Peer-Reviewed Publication of EscharEx® Mechanism of Action Study Assessing Its Effects on Biofilm and Microbial Loads
12/18/23 MediWound Ltd. (NASDAQ:MDWD) Stock Rockets 26% As Investors Are Less Pessimistic Than Expected
MDWD Chatroom

User Image MajorBlockbuster Posted - 1 day ago

@Do_Not_Poke_The_Bear Add $MDWD it’s a winner

User Image MajorBlockbuster Posted - 2 days ago

$MDWD Balance Sheet Highlights As of December 31, 2023, the Company’s cash, restricted cash, and investments were $42.1 million, compared to $34.1 million reported on December 31, 2022. In the first quarter of 2023, the Company raised a gross amount of $27.5 million through a registered direct offering. The company used $17.1 million to fund its activities. The existing cash and restricted cash, and investments will provide sufficient funds through profitability.

User Image MajorBlockbuster Posted - 2 days ago

@oldwisetrader as always I am holding . For those with a shorter timeline I am buying $MDWD . Worth your time.

User Image MajorBlockbuster Posted - 2 days ago

$MDWD any theory on why they don’t charge enough for their product to be profitable? Thanks.

User Image GlobalInsights Posted - 2 days ago

$MDWD Tome to surpass $20 then on to $30!

User Image OldManGrumble Posted - 3 days ago

$MDWD It’s just under $20 a share now. It paused, consolidated, it seems like last month, but it’s moving up again.

User Image chachachaching Posted - 3 days ago

$HKD The 3 year low on $MDWD is $7.1. You realize he got in before the 1:7 RS at $3.20, which puts his cost at $22.4 per share post split and his position is still underwater, right?

User Image EpiCRise98 Posted - 3 days ago

$MDWD $HKD was talking to a fellow trader who went against the grain and followed his DD. He basically got laughed out of the board his decision. Go long and win HKD ✅

User Image EpiCRise98 Posted - 3 days ago

$MDWD great HODL , 🎯28✅ riding house now 😊

User Image Me0wth Posted - 3 days ago

$MDWD fun times 😺💰

User Image MajorBlockbuster Posted - 3 days ago

$MDWD how are we looking for Russell 3000 inclusion?

User Image MajorBlockbuster Posted - 04/30/24

$MDWD Bought more.

User Image MajorBlockbuster Posted - 04/30/24

$INMB $MDWD Bought more.

User Image GlobalInsights Posted - 04/30/24

$MDWD Positive publication. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11041863/

User Image GlobalInsights Posted - 04/30/24

$MDWD Quant algorithms should keep this moving upward. Add some positive news, like basal cell carcinoma treatment partnership and this will gap up significantly. Shares still extremely undervalued.

User Image GlobalInsights Posted - 04/29/24

$MDWD Maybe getting close to a deal on their basal cell carcinoma treatment?

User Image MajorBlockbuster Posted - 04/26/24

$MDWD bought more. This is a winner.

User Image DonCorleone77 Posted - 04/25/24

$MDWD Noice!! MediWound to present data from EscharEx Phase II studies MediWound announced that recent clinical data from EscharEx Phase II studies will be presented throughout May 2024 at the largest, most prestigious annual meetings in the field of chronic wound care: the European Wound Management Association, the Wound Healing Society, and the Symposium on Advanced Wound Care. The oral presentations on EscharEx will include: Comparative data of EscharEx vs. SANTYL that demonstrate EscharEx's superiority over the current leading enzymatic debridement agent; New analyses from the ChronEx phase II study, showing high correlation between wound bed preparation and wound healing; These data indicate that EscharEx could substantially improve wound care for patients with debilitating chronic wounds, providing significant benefits over the current standard of care. Additionally, the findings support the design and endpoints of the upcoming Phase III study, which is expected to begin in the second half of 2024. "We are delighted to present the results of additional analyses from EscharEx Phase II studies in chronic hard-to-heal wounds, including the positive comparative data with SANTYL(R), the current dominant standard of care for enzymatic debridement," said Dr. Robert J. Snyder, Chief Medical Officer of MediWound. "With its robust efficacy, favorable safety profile, and multimodal mechanistic effects demonstrated in these Phase II studies, we believe that EscharEx can significantly advance wound care and has the potential to become a major player in the global wound care market."

User Image MajorBlockbuster Posted - 04/25/24

MediWound to Present New Data from EscharEx® Phase II Studies at Three Leading Wound Care Conferences | MediWound $MDWD https://ir.mediwound.com/news-releases/news-release-details/mediwound-present-new-data-escharexr-phase-ii-studies-three

User Image Stock_Titan Posted - 04/25/24

$MDWD MediWound to Present New Data from EscharEx® Phase II Studies at Three Leading Wound Care Conferences https://www.stocktitan.net/news/MDWD/medi-wound-to-present-new-data-from-eschar-ex-r-phase-ii-studies-at-lovijieykko5.html

User Image OldManGrumble Posted - 04/24/24

$MDWD es mi amigo.

User Image GlobalInsights Posted - 04/24/24

$MDWD If it can hit a 52w high tomorrow or Friday then the upward march will continue!

User Image OldManGrumble Posted - 04/23/24

$MDWD I do not underestimate this company's stock.

User Image MajorBlockbuster Posted - 04/19/24

$LCTX $CRSP $MDWD https://x.com/iancassel/status/1417656865010470912?s=12

User Image kiwitc2000 Posted - 04/17/24

$MDWD Added here.

User Image GlobalInsights Posted - 04/17/24

$MDWD New 52w high achieved, 2nd in a row, upward momentum confirmed. Algorithms should take this higher.

User Image GlobalInsights Posted - 04/17/24

$MDWD To keep the upside going we need to make a series of consecutive 52w highs. Can we make it the second today? Pre market suggests so!

User Image kiwitc2000 Posted - 04/16/24

$ICCM Not sure that being Israeli is what causing the price flatlining. For example, look at Israeli biotech $MDWD that's flying today, closing in on 19 in after market. I'm holding positions in both BTW.

User Image OldManGrumble Posted - 04/16/24

$MDWD - hurray!

User Image Me0wth Posted - 04/16/24

$MDWD long term hold 😺💰

Analyst Ratings
HC Wainwright & Co. Buy Mar 22, 24
HC Wainwright & Co. Buy Jan 16, 24
HC Wainwright & Co. Buy Nov 22, 23
HC Wainwright & Co. Buy Sep 21, 23
Oppenheimer Outperform Aug 17, 23
HC Wainwright & Co. Buy Aug 17, 23
Oppenheimer Outperform May 31, 23
HC Wainwright & Co. Buy May 31, 23
HC Wainwright & Co. Buy Mar 17, 23